SAN FRANCISCO--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that new data presented at the Heart Rhythm Society’s 32nd Annual Scientific Sessions in San Francisco confirm the diagnostic value of Microvolt T-wave Alternans (MTWA) testing in identifying patients at risk of sudden cardiac arrest (SCA). The pooled analysis of 2,883 patients shows that MTWA is a statistically significant predictor of SCA in patients whose heart muscle is damaged (ejection fraction = 35%), as well as those with more preserved cardiac function (ejection fraction > 35%).
